| Objective: To evaluate the efficacy and safety of short-term rivaroxaban and dabigatran etexilate after one-stop surgery in patients with atrial fibrillation.Methods: Multicenter retrospective study including 233 patients who underwent atrial fibrillation ablation combined with left atrial appendage closure(LAAC)one-stop surgery and received rivaroxaban or dabigatran etexilate for 45 days from April 2018 to October 2021.The patient was followed up 45 days,3 months,6 months and 12 months after the operation to assess safety(death,major hemorrhage events),efficiency(any stroke,thromboembolism,and device-related thrombosis),and composite endpoint events(death,major hemorrhage,stroke,thromboembolism,and device-related thrombosis).Results: A total of 233 patients with a mean age of 67.7±10.2 years were included in this study.A total of(4/233,1.7%)patients died,(1/233,0.4%)patients had major hemorrhage,(2/233,0.9%)patients had device-related thrombosis(DRT),and(3/233,1.3%)patients had lower limb deep vein thrombosis(DVT)during the 1-year follow-up.Patients were divided into the rivaroxaban and dabigatran etexilate groups according to the different drugs they were taking after surgery,and there was no significant difference in the incidence of adverse events between the two groups.However,a higher incidence of mortality(3.2% Vs 1.2%),major hemorrhage(1.6% Vs 0%),DRT(3.2% Vs 0%)and lower limb DVT(1.6% Vs 1.2%)was observed in patients receiving dabigatran etexilate.By Kaplan-Meier curve analysis,the incidence of safety endpoint events(log-rank P=0.09),efficacy endpoint events(log-rank P=0.03)and composite endpoint events(log-rank P=0.01)was lower in the rivaroxaban group compared with the dabigatran etexilate group.Conclusion: Short-term rivaroxaban or dabigatran etexilate after one-stop surgery in patients with atrial fibrillation was safe and effective,and rivaroxaban had a lower rate of serious adverse events compared with dabigatran. |
PDF Full Text Request